4.6 Article

Collagenase-Expressing Salmonella Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth

Journal

CANCERS
Volume 13, Issue 14, Pages -

Publisher

MDPI
DOI: 10.3390/cancers13143565

Keywords

pancreatic ductal adenocarcinoma; targeted therapies; therapeutic resistance; tumor microenvironment; desmoplasia; collagen; collagenase; attenuated Salmonella typhimurium

Categories

Funding

  1. COH Shared Resources grant
  2. National Cancer Institute of the National Institutes of Health [P30CA033572]

Ask authors/readers for more resources

This study characterized a novel bacterial-based agent engineered to degrade collagen within pancreatic tumors, resulting in significant reductions in intratumoral collagen content and pro-tumor immune cell subsets in mouse models of pancreatic cancer. Ultimately, the treatment modified the intratumoral immune landscape to potentially enhance immunotherapy outcomes.
Simple Summary The deposition of fibrotic tissue within pancreatic tumors acts as a physical barrier to therapeutic treatment. Collagen constitutes a large part of this barrier and serves as an ideal target to improve delivery and efficacy of anti-cancer treatments. This study characterizes a novel bacterial-based agent engineered to degrade collagens present only in pancreatic tumor tissue. Treatment using our collagen-degrading bacteria in mouse models of pancreatic cancer resulted in significant decreases in intratumoral collagen content and pro-tumor immune cell subsets, ultimately enhancing the efficacy of immunotherapy. These results support the idea that overcoming fibrosis in pancreatic cancer can dramatically improve therapeutic outcomes. Therapeutic resistance in pancreatic ductal adenocarcinoma (PDAC) can be attributed, in part, to a dense extracellular matrix containing excessive collagen deposition. Here, we describe a novel Salmonella typhimurium (ST) vector expressing the bacterial collagenase Streptomyces omiyaensis trypsin (SOT), a serine protease known to hydrolyze collagens I and IV, which are predominantly found in PDAC. Utilizing aggressive models of PDAC, we show that ST-SOT selectively degrades intratumoral collagen leading to decreases in immunosuppressive subsets, tumor proliferation and viability. Ultimately, we found that ST-SOT treatment significantly modifies the intratumoral immune landscape to generate a microenvironment that may be more conducive to immunotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biotechnology & Applied Microbiology

Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity

John P. Murad, Dileshni Tilakawardane, Anthony K. Park, Lupita S. Lopez, Cari A. Young, Jackson Gibson, Yukiko Yamaguchi, Hee Jun Lee, Kelly T. Kennewick, Brenna J. Gittins, Wen-Chung Chang, Chau P. Tran, Catalina Martinez, Anna M. Wu, Robert E. Reiter, Tanya B. Dorff, Stephen J. Forman, Saul J. Priceman

Summary: CAR T cell therapy has shown impressive clinical responses in hematological malignancies but limited effectiveness in solid tumors. Treatment with PSCA-CAR T cells for metastatic prostate and pancreas cancer requires cyclophosphamide preconditioning for efficacy, without observed toxicities in normal tissues expressing PSCA.

MOLECULAR THERAPY (2021)

Article Hematology

Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation

Zachary Davis, Martin Felices, Todd Lenvik, Sujan Badal, Joshua T. Walker, Peter Hinderlie, James L. Riley, Daniel A. Vallera, Bruce R. Blazar, Jeffrey S. Miller

Summary: The study showed that functional PD-1 is expressed on resting human NK cells in healthy individuals and reconstituting NK cells early after allo-HSCT. Blocking PD-1 on resting NK cells enhanced their function against PD-L1-expressing tumor lines, indicating the potential for PD-1 blockade in enhancing NK cell-mediated antitumor control.

BLOOD ADVANCES (2021)

Review Biochemistry & Molecular Biology

Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges

Mehrdad Hefazi, Sara Bolivar-Wagers, Bruce R. Blazar

Summary: This review provides the latest preclinical and clinical data on Treg cell therapy in the context of GVHD, highlighting the importance of T cell therapy in preventing and treating GVHD, and discussing future research directions and challenges.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Medicine, Research & Experimental

Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells

Darlene A. Monlish, Kevin J. Beezhold, Pailin Chiaranunt, Katelyn Paz, Nathan J. Moore, Andrea K. Dobbs, Rebecca A. Brown, John A. Ozolek, Bruce R. Blazar, Craig A. Byersdorfer

Summary: Research suggests that AMPK plays a significant role in alloreactive T cells posttransplant, with its absence lessening the severity of GVHD without compromising antileukemia responses or impairing immune reconstitution. This highlights potential for AMPK inhibition as an innovative approach to mitigate GVHD while preserving graft-versus-leukemia responses and maintaining robust immune reconstitution.

JCI INSIGHT (2021)

Review Hematology

Emerging approaches to improve allogeneic hematopoietic cell transplantation outcomes for nonmalignant diseases

Zachariah DeFilipp, Mehrdad Hefazi, Yi-Bin Chen, Bruce R. Blazar

Summary: This article discusses the application of transplantation in the treatment of congenital or acquired nonmalignant blood diseases. Unlike patients with hematologic malignancies, the priority for nonmalignant blood disease patients is to avoid graft-versus-host disease, and emerging therapeutic methods hold promise for advancing transplantation care.

BLOOD (2022)

Article Hematology

Donor bone marrow-derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice

Rachael C. Adams, Dylan Carter-Cusack, Samreen N. Shaikh, Genesis T. Llanes, Rebecca L. Johnston, Gregory Quaife-Ryan, Glen Boyle, Lambros T. Koufariotis, Andreas Moller, Bruce R. Blazar, Jana Vukovic, Kelli P. A. MacDonald

Summary: This study reveals the development mechanism of chronic GVHD in the CNS after stem cell transplantation, including neuroinflammation and abnormal gene expression. The study found that donor-derived macrophages play an important role in CNS cGVHD.

BLOOD (2022)

Article Biochemistry & Molecular Biology

Analyses and Correlation of Pathologic and Ocular Cutaneous Changes in Murine Graft versus Host Disease

Robert B. Levy, Hazem M. Mousa, Casey O. Lightbourn, Eric J. Shiuey, David Latoni, Stephanie Duffort, Ryan Flynn, Jing Du, Henry Barreras, Michael Zaiken, Katelyn Paz, Bruce R. Blazar, Victor L. Perez

Summary: Graft versus host disease (GVHD) is a complication of stem cell transplants, and ocular involvement occurs in a high percentage of patients. This study found a correlation between ocular and cutaneous involvement in chronic GVHD, suggesting shared immune mechanisms. Evaluating the ocular surface in patients with skin involvement may be valuable.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Targeted Depletion of Hyaluronic Acid Mitigates Murine Breast Cancer Growth

Vic Zamloot, Nancy Danielle Ebelt, Catherine Soo, Shweta Jinka, Edwin R. Manuel

Summary: Breast cancer often contains excessive stromal matrix components, such as hyaluronic acid (HA), which plays important roles in tumor progression and spread. This study shows that an attenuated Salmonella typhimurium secreting a bacterial hyaluronidase (YS-HAse) can degrade HA within murine breast tumors, resulting in enhanced tumor permeability and growth control. YS-HAse represents a promising new therapeutic approach that could be used alongside current treatments to improve their delivery and effectiveness.

CANCERS (2022)

Article Hematology

Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials

Zachariah DeFilipp, Haesook T. Kim, Zhongming Yang, John Noonan, Bruce R. Blazar, Stephanie J. Lee, Steven Z. Pavletic, Corey Cutler

Summary: This study found that Belumosudil treatment was associated with lung-specific clinical responses in patients with BOS. Lung-specific responses were more commonly observed in patients with less advanced disease.

BLOOD ADVANCES (2022)

Article Oncology

5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia

Nancy D. Ebelt, Edwin R. Manuel

Summary: Cancer cells can escape surveillance through epigenetic modifications, while hypomethylating agents (HMAs) have shown promise as a milder treatment option for leukemia patients. In this study, HMAs were tested on murine leukemias and found to re-establish immune-related gene expression, reduce leukemic burden, and improve survival. However, resistance and immune checkpoint protein expression were observed.

CANCERS (2023)

Article Medicine, Research & Experimental

IL-33 acts as a costimulatory signal to generate alloreactive Th1 cells in graft-versus-host disease

Gaelen K. Dwyer, Lisa R. Mathews, Jose A. Villegas, Anna Lucas, Anne Gonzalez de Peredo, Bruce R. Blazar, Jean-Philippe Girard, Amanda C. Poholek, Sanjiv A. Luther, Warren Shlomchik, Heth R. Turnquist

Summary: In allogeneic hematopoietic stem cell transplantation (alloHCT), recipient conditioning releases damage-associated molecular patterns (DAMPs) that generate proinflammatory antigen-presenting cells (APCs) secreting IL-12, which drives the response of donor Th1 cells, leading to graft-versus-host disease (GVHD). However, there are other mechanisms through which alloreactive T cell responses are initiated by directly acting on donor CD4(+) T cells. Among these mechanisms, fibroblastic reticular cell-derived DAMP IL-33 plays a critical role by enhancing T cell expansion and differentiation through the activation of T cell signaling pathways in response to alloantigen, resulting in GVHD.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Review Medicine, Research & Experimental

Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease

Gerard Socie, Leslie S. Kean, Robert Zeiser, Bruce R. Blazar

Summary: In the past 15 years, understanding of the pathophysiologic mechanisms underlying GVHD has significantly improved, but translation to clinical care has been slow and the clinical utility of new therapeutic agents has been inconsistent. New tools in immunology have recently been applied in the field of clinical GVHD, but there is a relative paucity of mechanistic insights into human translational research.

JOURNAL OF CLINICAL INVESTIGATION (2021)

No Data Available